Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Vimseltinib Stands Out as An Alternative to Surgery for Select Patients With Diffuse TGCT

March 6th 2025

R. Lor Randall, MD, FACS, discusses the significance of the FDA approval of vimseltinib for patients with symptomatic TGCT.

Dr Tap on the FDA Approval of Vimseltinib for Symptomatic TGCT

March 5th 2025

William D. Tap, MD, discusses the FDA approval of vimseltinib for patients with symptomatic TGCT and this agent's role in the treatment paradigm.

T-DXd’s Role Expands Into HER2-Low/-Ultralow Metastatic Breast Cancer, Reinforcing Need for Enhanced HER2 Testing

March 5th 2025

Aditya Bardia, MD, MPH, FASCO, discusses how the FDA approval of T-DXd for HER2-low/-ultralow metastatic breast cancer has affected the treatment paradigm.

SWOG S1815 Shows Need for Subgroup-Specific Triplet Chemotherapy Assessment in Biliary Tract Cancer

March 5th 2025

Rachna Shroff, MD, MS, FASCO, discusses the potential role for nab-paclitaxel plus gemcitabine and cisplatin in select patients with biliary tract cancers.

Toxicity, Sequencing Considerations Are Key for Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer

March 4th 2025

Brandon G. Smaglo, MD, FACP, discusses upfront treatment considerations for patients with metastatic pancreatic cancer.

Dr Lee on the Rationale for Using Integrative Medicine in Patients With GI Cancers

March 4th 2025

Richard T. Lee, MD, discusses research showing the benefits of acupuncture, ginger, and ginseng for improving symptoms in patients with GI cancers.

Dr Vlachou on Primary Tumor Responses With Enfortumab Vedotin in Upper Tract Urothelial Cancer

March 4th 2025

Evangelia Vlachou, MD, discusses response rates with enfortumab vedotin alone or with pembrolizumab in patients with upper tract urothelial cancer.

Dr Li on the Casdozokitug/Atezolizumab/Bevacizumab in Unresectable HCC

February 28th 2025

Daneng Li, MD, discusses a trial evaluating casdozokitug plus atezolizumab and bevacizumab in unresectable, locally advanced or metastatic HCC.

Immunotherapy Combinations Reign Supreme in Upfront Melanoma Management

February 28th 2025

Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.

Ipilimumab Injection Plus Sintilimab Receives Priority Review in China for MSI-H/dMMR Colon Cancer

February 27th 2025

China’s NMPA has granted priority review to an NDA for neoadjuvant ipilimumab injection plus sintilimab in MSI-H or dMMR colon cancer.

FDA Grants Fast Track Designation to PYX-201 for Recurrent/Metastatic HNSCC

February 27th 2025

PYX-201 has received fast track designation from the FDA for patients with recurrent or metastatic HNSCC following progression with chemoimmunotherapy.

Multidisciplinary Collaboration Is Vital for Timely, Definitive Diagnosis of Indolent Systemic Mastocytosis

February 26th 2025

Andrew Kuykendall, MD, discusses the importance of a nuanced, multidisciplinary approach to expedite the diagnosis of indolent systemic mastocytosis.

Dr Daneshmand on Using TAR-200 to Address Unmet Needs in BCG-Unresponsive NMIBC

February 25th 2025

Sia Daneshmand MD, discusses how the intravesical therapy TAR-200 could address unmet needs for patients with high-risk, BCG-unresponsive NMIBC with CIS.

Updated Clinical Trial Data Reflect Efforts to Optimize IO Combos in Non-ccRCC and MIBC, Fine-Tune ADT-Based Regimens in Prostate Cancer

February 25th 2025

Pedro Barata, MD, provides insights on key updates in RCC, MIBC, and prostate cancer, as discussed during a State of the Science Summit™.

Isatuximab Plus VRd Wins Japanese Approval for Newly Diagnosed Myeloma

February 25th 2025

Isatuximab plus VRd has been approved in Japan for transplant-ineligible, newly diagnosed multiple myeloma.

FDA Grants Priority Review to Perioperative Pembrolizumab in Resectable HNSCC

February 25th 2025

The FDA has granted priority review to the sBLA for perioperative pembrolizumab plus adjuvant radiotherapy in resectable locally advanced HNSCC.

Dr Awan on Patient Characteristics Associated With CAR T-Cell Candidacy in CLL

February 24th 2025

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Dr Daneshmand on Findings From the SunRISE-1 Trial of TAR-200 in BCG-Unresponsive NMIBC

February 24th 2025

Sia Daneshmand MD, discusses key efficacy findings from the SunRISE-1 trial of TAR-200 in patients with BCG-unresponsive, high-risk NMIBC with CIS.

Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management

February 24th 2025

Pedro Barata, MD, discusses the expansion of radioligand therapies and the identification of novel targets beyond PSMA in prostate cancer.

TAR-200 Is Poised to Become a Targeted, Tolerable Addition to BCG-Unresponsive NMIBC Treatment Arsenal

February 24th 2025

Sia Daneshmand, MD, discusses how TAR-200 addresses an unmet need for patients with BCG-unresponsive, high-risk NMIBC.